Analystreport

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is now covered by analysts at Canaccord Genuity. They set a "buy" rating and a $27.00 price target on the stock.

Oramed Pharmaceuticals Inc.  (ORMP) 
Last oramed pharmaceuticals inc. earnings: 4/6 04:46 pm Check Earnings Report
US:NASDAQ Investor Relations: oramed.com/investors